SCHEMBL20317385

SCHEMBL20317385

CC(C)C(=O)COCCOCCN1CCN(C(C)C)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HRH1 P35367 3/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ HRH2 P25021 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ DRD3 P35462 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ TEK Q02763 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ MAOB P27338 5/20 0.37
▸ TACR1 P25103 2/20 0.36
▸ DAO P14920 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19598467 0.97 HRH1 (0.40) ALDH1A1LMNAGAAMAPTMAPK1
SCHEMBL20317530 0.85 PIK3CD (0.44) ALDH1A1LMNAGAAMAPTMAPK1
SCHEMBL23350175 0.85 HRH1 (0.39) ALDH1A1LMNAGAAMAPTMAPK1
SCHEMBL19599560 0.84 PAOX (0.42) ALDH1A1HRH1SLC6A2HRH2HTR2A
SCHEMBL24372842 0.84 HRH2 (0.43) ALDH1A1LMNAGAAMAPTMAPK1
SCHEMBL21456135 0.83 ALDH1A1 (0.40) ALDH1A1GAAHRH1SLC6A2HRH2
SCHEMBL21477049 0.83 HRH1 (0.41) ALDH1A1LMNAGAAMAPTMAPK1
SCHEMBL21105813 0.83 HSD11B1 (0.42) MAPTHRH1SLC6A2HRH2HTR2A
SCHEMBL21106222 0.81 HRH1 (0.35) HRH1SLC6A2HRH2HTR2ASLC6A4
SCHEMBL19599564 0.80 HRH1 (0.40) ALDH1A1LMNAGAAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11857519-B2 Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide ARVINAS OPERATIONS, INC. (US) 2024-01-02 — — US disclosed
US-20180177750-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE ARVINAS OPERATIONS, INC. 2018-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11857519-B2 Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide CRBN, MDM2, VHL ALDH1A1 3688/4885LMNA 1341/4885GAA 486/4885
US-20180177750-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE CRBN, MDM2, VHL ALDH1A1 3688/4885LMNA 1341/4885GAA 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback